ISA103 / ISA Pharma - LARVOL DELTA

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma (PRNewswire) - "ISA Pharmaceuticals, B.V...and Cancer Focus Fund, LP...today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer....In the two-part open label Phase 1b/2 trial, ISA103 will be tested in combination with standard of care checkpoint blocker immunotherapies."

Financing • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Uveal Melanoma

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines (PRNewswire) - “ISA Pharmaceuticals…announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines…The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials. It provides an overview of the numerous mechanisms cancer cells use to evade treatment as well as strategies that can be utilized to significantly enhance clinical efficacy of immunotherapies…ISA's T cell activating SLP programs include: ISA101b for Human Papilloma Virus type 16 (HPV16) induced tumors…ISA103 for cancers that over-express PRAME…”

Clinical • Oncology • Solid Tumor